Sponsor Check › Salus Scientific › Issuer
Corporation · organized in SOUTH CAROLINA · formed 2021 · CHARLESTON, SC · SEC CIK 1952070
Part of sponsor group: Salus Scientific (2 issuers, 7 filings) · grouped because: shared people · confidence 70% · Not the same sponsor? Request a correction
Data last updated: Oct 23, 2026, 5:45 PM ET · Latest filing by this issuer: Oct 22, 2026 · Courts (RECAP) last checked: not yet · SEC enforcement last checked: not yet
The five facts investors ask about first. Each section states what was searched and when. Items still in human review are not shown.
Not yet searched.
Sources to be searched: CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not yet searched. PACER: not searched (RECAP only). · Search queued. Results are added automatically; check back later or follow this page to be notified.
Not yet searched.
Sources to be searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. State securities regulator actions: not yet searched. · Search queued. Results are added automatically; check back later or follow this page to be notified.
Not yet searched.
Sources to be searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not yet searched. PACER: not searched (RECAP only). · Search queued. Results are added automatically; check back later or follow this page to be notified.
Coming soon.
What will be compared: what the sponsor says publicly (website, marketing materials, claimed profile) against what public records show — SEC Form D filings, Form ADV adviser registration, and state business records. Every comparison is reviewed by a person before it is published.
No comparisons published yet.
Sources to be compared: sponsor public claims · SEC Form D · SEC Form ADV (IAPD) · state business records · As of Oct 23, 2026, 9:13 PM ET.
1 of 4 offerings reports sales commissions totalling $1,300,000; 0 report finder's fees; 4 report proceeds to related persons totalling $2,875,000. (includes amounts the issuer reported as estimates)
| Source | Offering (latest filing) | Sales commissions | Finder's fees | To insiders | Paid to sell it |
|---|---|---|---|---|---|
| EDGAR ↗ | Nov 10, 2022 D File 021-464536 | $0 | $0 | $975,000 (est.) Salaries | None listed |
| EDGAR ↗ | Oct 29, 2024 D File 021-528016 | $0 | $0 | $300,000 (est.) Salaries | None listed |
| EDGAR ↗ | Aug 5, 2026 D/A File 021-572894 | $0 | $0 | $700,000 (est.) | None listed |
| EDGAR ↗ | Oct 22, 2026 D File 021-602167 | $1,300,000 (est.) | $0 | $900,000 (est.) | Jeffrey S. Goodman BrokerCheck CRD 002607530 ↗ via Ankura Capital Advisors, LLC (CRD 000114155) |
As reported by the issuer on Form D (Items 12–15), latest filing per offering. "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates.
Each filing as reported by the issuer. Open a row for the full plain-English detail.
| Filing | Form D filed Oct 22, 2026 SEC file no. 021-602167 · accession 0001085146-26-000912 |
|---|---|
| Raise progress | $0 sold of $30,000,000 offered (0%) · $30,000,000 remaining |
| Filing timing | Date of first sale: Yet to occur · Form D filed: Oct 22, 2026 Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 0 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $250,000 |
| Securities offered | Equity |
| Industry / issuer size | Other Health Care · revenue range: Decline to Disclose |
| Who is paid to sell it | Jeffrey S. Goodman — FINRA BrokerCheck CRD 002607530 ↗ · associated broker-dealer: Ankura Capital Advisors, LLC (CRD 000114155 ↗) Solicits in: CA, CO, FL, GA, NJ, NY, OH, TN, UT |
| Money to insiders | Sales commissions: $1,300,000 (est.) · Finder's fees: $0 · Proceeds to officers, directors, promoters: $900,000 (est.) |
| Signed by | Jon A. Wallace, Officer General Counsel (Oct 22, 2026) |
| Market context | Minimum investment: $250,000. Typical range for similar offerings: $10,000–$54,310. Offering size: $30,000,000. Typical range: $829,831–$9,999,998. Investors: 0. Typical range: 2–15. "Similar" = Other Health Care offerings claiming 506(b) filed in the last 5 years (4,189 filings); ranges are the middle half (25th–75th percentile). No ranking or score. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the EDGAR daily index |
| Filing | Form D/A (amendment) filed Aug 5, 2026 · amends 0001085146-26-000178 ↗ SEC file no. 021-572894 · accession 0001085146-26-000560 |
|---|---|
| Raise progress | $10,120,000 sold of $10,120,000 offered (100%) · $0 remaining |
| Filing timing | Date of first sale: Jan 22, 2026 · Form D filed: Aug 5, 2026 (195 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 275 days (0.8 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 1 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $99,720 |
| Securities offered | Equity |
| Industry / issuer size | Other Health Care · revenue range: $1,000,001 - $5,000,000 |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $700,000 (est.) |
| Signed by | Jon A. Wallace, Officer General Counsel (Aug 5, 2026) |
| Changes vs prior filing | total sold: $138,500 → $10,120,000 total offering: $8,019,192 → $10,120,000 Compared with the D filed Feb 9, 2026 (EDGAR ↗). Amendment history as filed; no conclusion is drawn. |
| Market context | Minimum investment: $99,720. Typical range for similar offerings: $10,000–$54,310. Offering size: $10,120,000. Typical range: $829,831–$9,999,998. Investors: 1. Typical range: 2–15. "Similar" = Other Health Care offerings claiming 506(b) filed in the last 5 years (4,189 filings); ranges are the middle half (25th–75th percentile). No ranking or score. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set |
| Filing | Form D filed Feb 9, 2026 SEC file no. 021-572894 · accession 0001085146-26-000178 |
|---|---|
| Raise progress | $138,500 sold of $8,019,192 offered (2%) · $7,880,692 remaining |
| Filing timing | Date of first sale: Jan 22, 2026 · Form D filed: Feb 9, 2026 (18 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 275 days (0.8 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 1 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $99,720 |
| Securities offered | Equity |
| Industry / issuer size | Other Health Care · revenue range: $1,000,001 - $5,000,000 |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $700,000 (est.) |
| Signed by | Jon A. Wallace, Officer General Counsel (Feb 6, 2026) |
| Market context | Minimum investment: $99,720. Typical range for similar offerings: $10,000–$54,310. Offering size: $8,019,192. Typical range: $829,831–$9,999,998. Investors: 1. Typical range: 2–15. "Similar" = Other Health Care offerings claiming 506(b) filed in the last 5 years (4,189 filings); ranges are the middle half (25th–75th percentile). No ranking or score. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set |
| Filing | Form D filed Oct 29, 2024 SEC file no. 021-528016 · accession 0001952070-24-000003 |
|---|---|
| Raise progress | $0 sold of $2,000,000 offered (0%) · $2,000,000 remaining |
| Filing timing | Date of first sale: Yet to occur · Form D filed: Oct 29, 2024 Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 0 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $25,000 |
| Securities offered | Equity; Option, warrant or other right to acquire |
| Industry / issuer size | Other Health Care · revenue range: $1 - $1,000,000 |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $300,000 (est.) Salaries |
| Signed by | Jon A. Wallace, Officer General Counsel (Oct 29, 2024) |
| Market context | Minimum investment: $25,000. Typical range for similar offerings: $10,000–$54,310. Offering size: $2,000,000. Typical range: $829,831–$9,999,998. Investors: 0. Typical range: 2–15. "Similar" = Other Health Care offerings claiming 506(b) filed in the last 5 years (4,189 filings); ranges are the middle half (25th–75th percentile). No ranking or score. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set |
| Filing | Form D filed Nov 10, 2022 SEC file no. 021-464536 · accession 0001952070-22-000001 |
|---|---|
| Raise progress | $335,000 sold of $2,000,000 offered (17%) · $1,665,000 remaining |
| Filing timing | Date of first sale: Oct 27, 2022 · Form D filed: Nov 10, 2022 (14 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 1,458 days (4.0 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 5 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $25,000 |
| Securities offered | Equity |
| Industry / issuer size | Biotechnology · revenue range: $1 - $1,000,000 |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $975,000 (est.) Salaries |
| Signed by | Todd Flohr, CEO (Nov 10, 2022) |
| Market context | Minimum investment: $25,000. Typical range for similar offerings: $10,000–$50,000. Offering size: $2,000,000. Typical range: $2,000,000–$19,999,994. Investors: 5. Typical range: 2–16. "Similar" = Biotechnology offerings claiming 506(b) filed in the last 5 years (3,253 filings); ranges are the middle half (25th–75th percentile). No ranking or score. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set |
All Form D filings for this CIK on SEC EDGAR ↗. History: 2 new offerings in the last 12 months · most recent filing Oct 22, 2026 · industry as reported over time: Biotechnology → Other Health Care.
| Name | Relationship | Address state | On filings | Also listed on |
|---|---|---|---|---|
| C. William Martin | Director | SC | Oct 22, 2026 | — |
| Jon Wallace | Executive Officer, Director | SC | Oct 29, 2024 → Oct 22, 2026 | — |
| Keith Rosmarin | Executive Officer | SC | Oct 29, 2024 → Oct 22, 2026 | — |
| Richard Moore | Director | SC | Oct 29, 2024 → Oct 22, 2026 | — |
| Ronald Sancho | Director | SC | Oct 22, 2026 | — |
| Ryan Majoria | Director | SC | Oct 29, 2024 → Oct 22, 2026 | 1 other issuer |
| Todd Flohr | Executive Officer, Director CEO | SC | Nov 10, 2022 → Oct 22, 2026 | — |
| William Buchanan | Director | SC | Oct 29, 2024 → Oct 22, 2026 | — |
| Ryan Sancho | Director | SC | Feb 9, 2026 → Aug 5, 2026 | — |
Executive officers, directors and promoters as self-reported by the issuer. Licensed persons: FINRA BrokerCheck ↗ · SEC IAPD ↗.
Other issuers listing the same people:
Shared address: this business address appears on no other issuer's filings in our index.
Not yet searched. Sources to be searched: SEC Investment Adviser Public Disclosure (IAPD) firm search — registered and exempt reporting advisers · Search queued. Results are added automatically; check back later.
Not yet collected. We store official links only (company website, verified via a profile claim) and the earliest archived date of the website; never personal or family accounts.
Export this report as PDF (all source links + data timestamp; members)
No corrections have been requested for this page.
The complete public-record profile for Salus Scientific Corp., plus the weekly new-filings list.
Only "Connect me" shares your details — with this sponsor, at a flat price we charge them, never tied to whether you invest. "Just researching" shares nothing.
Free. Tell us what's wrong and, if you can, where the correct public record is. Every request is logged with its status (received → under review → fixed / confirmed with source).
Sponsors may add a sourced explanation next to any fact on this page. Reviewed before publishing; never edits the public record.
Free. Get the "Claimed by sponsor" chip and a verified contact for corrections. Claiming never changes the public-record section.